Related Experiment Video
Updated: Oct 25, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Glioblastoma: Emerging Treatments and Novel Trial Designs
Vincenzo Di Nunno1, Enrico Franceschi1, Alicia Tosoni1
1Department of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, Italy.
Abstract:
Management of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are emerging. The expanding availability of innovative compounds requires the design of a new generation of clinical trials, testing experimental compounds in a short time and tailoring the sample cohort based on molecular and clinical behaviors. In this review, we focused our attention on the assessment of promising novel treatment approaches, discussing novel trial design and possible future fields of development in this setting.
Insights
New glioblastoma treatments are emerging, requiring innovative clinical trial designs. This review assesses novel therapeutic strategies and future research directions for recurrent glioblastoma.
Area of Science:
- Neuro-oncology
- Clinical trial design
- Molecular biology
Background:
- Glioblastoma (GBM) presents significant treatment challenges, particularly for recurrent disease.
- Limited efficacy of current systemic treatments necessitates novel therapeutic approaches.
- Advances in understanding GBM biology and molecular mechanisms drive new treatment strategies.
Purpose of the Study:
- To review promising novel treatment approaches for glioblastoma.
- To discuss the design of next-generation clinical trials for experimental compounds.
- To explore future directions in glioblastoma therapeutic development.
Main Methods:
- Literature review of recent advancements in glioblastoma treatment.
- Analysis of emerging therapeutic compounds and their biological rationale.
- Discussion of innovative clinical trial designs tailored to molecular profiles.
Main Results:
- Several novel treatment strategies show promise for recurrent glioblastoma.
- Innovative trial designs are crucial for rapid evaluation of new compounds.
- Personalized approaches based on molecular and clinical characteristics are key.
Conclusions:
- Novel therapies and adaptive clinical trial designs are essential for advancing glioblastoma management.
- Future research should focus on molecularly targeted treatments and efficient trial methodologies.
- Optimizing treatment strategies requires a deep understanding of glioblastoma heterogeneity.
